Publications by authors named "Arlene Swern"

Claim this Profile
R
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
Jay L Patel, Mehrdad Abedi, Christopher R Cogle, Harry P Erba, Kathryn Foucar, Arlene S Swern

Int J Lab Hematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, Donna Reece, Ajay Nooka, Arlene S Swern

Blood Cancer J· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determining the Suitability of Registries for Embedding Clinical Trials in the United States: A Project of the Clinical Trials Transformation Initiative.
J Stephen Mikita, Jules Mitchel, Nicolle M Gatto, John Laschinger, James E Tcheng, Arlene S Swern

Ther Innov Regul Sci· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect MDS/AML Disease Registry.
Daniel A Pollyea, Tracy I George, Mehrdad Abedi, Rafael Bejar, Christopher R Cogle, Arlene S Swern

EJHaem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect CLL Registry.
Jeff P Sharman, Kim Cocks, Chadi Nabhan, Nicole Lamanna, Neil E Kay, Arlene S Swern

EJHaem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites.
Anthony Mato, Chadi Nabhan, Nicole Lamanna, Neil E Kay, David L Grinblatt, Arlene S Swern

Blood Adv· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.
Rafat Abonour, Lynne Wagner, Brian G M Durie, Sundar Jagannath, Mohit Narang, Arlene S Swern

Ann Hematol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect CLL cohort study.
Christopher R Flowers, Chadi Nabhan, Neil E Kay, Anthony Mato, Nicole Lamanna, Arlene S Swern

Leuk Lymphoma· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).
Mikkael A Sekeres, Arlene S Swern, Aristoteles Giagounidis, Alan F List, Dominik Selleslag

Blood Cancer J· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Xiaomei Ma, David P Steensma, Bart L Scott, Pavel Kiselev, Mary M Sugrue, Arlene S Swern

BMJ Open· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Rami Komrokji, Arlene S Swern, David Grinblatt, Roger M Lyons, Magnus Tobiasson

Oncologist· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
Anthony Mato, Chadi Nabhan, Neil E Kay, Nicole Lamanna, Thomas J Kipps, Arlene S Swern

Clin Lymphoma Myeloma Leuk· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early progression of disease as a predictor of survival in chronic lymphocytic leukemia.
Inhye E Ahn, Charles M Farber, Matthew S Davids, David L Grinblatt, Neil E Kay, Arlene S Swern

Blood Adv· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Hang Quach, Liam Fernyhough, Ross Henderson, Gillian Corbett, Bart Baker, Arlene Swern

Br J Haematol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.
Chadi Nabhan, Anthony Mato, Christopher R Flowers, David L Grinblatt, Nicole Lamanna, Arlene S Swern

BMC Cancer· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Lisa Pleyer, Hartmut Döhner, Hervé Dombret, John F Seymour, Andre C Schuh, Arlene S Swern

Int J Mol Sci· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres.
Anthony Mato, Chadi Nabhan, Neil E Kay, Mark A Weiss, Nicole Lamanna, Arlene S Swern

Br J Haematol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
David P Steensma, Medrdad Abedi, Rafael Bejar, Christopher R Cogle, Kathryn Foucar, Arlene S Swern

BMC Cancer· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash.
Lilia Weiss, Dianna Gary, Arlene S Swern, John Freeman, Mary M Sugrue

Ther Clin Risk Manag· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry.
David L Grinblatt, Mikkael A Sekeres, Rami S Komrokji, Arlene S Swern, Kristen A Sullivan

Leuk Lymphoma· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.
Pierre Fenaux, John F Seymour, Valeria Santini, Lew Silverman, Steven Gore, Arlene S Swern

Leuk Res· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia.
Chris L Pashos, Christopher R Flowers, Neil E Kay, Mark Weiss, Nicole Lamanna, Arlene S Swern

Support Care Cancer· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial.
Steven D Gore, Pierre Fenaux, Valeria Santini, John M Bennett, Lewis R Silverman, Arlene S Swern

Haematologica· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.
Rami S Komrokji, Jeffrey E Lancet, Arlene S Swern, Nianhang Chen, Jennifer Paleveda

Blood· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.
Asher A Chanan-Khan, Sagar Lonial, Donna Weber, Ivan Borrello, Robin Foà, Arlene S Swern

Int J Hematol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis